Trial · NCT06749613
Digestive Enzyme Formulation Intervention in IBS Patients Who Previously Clinically Responded to Mediterranean LFD
Irritable bowel syndrome (IBS) is a highly prevalent chronic functional gastrointestinal disorder. The cardinal symptoms include abdominal pain, flatulence, blo
- Status
- Recruiting
- Sponsor
- Attikon Hospital
- Study type
- Interventional
- Phase
- No phase
- Enrollment
- 40 participants (planned)
- Start
- Dec 10, 2024
- Primary completion
- Oct 10, 2025
- Conditions
- Irritable Bowel Syndrome
Summary
Irritable bowel syndrome (IBS) is a highly prevalent chronic functional gastrointestinal disorder. The cardinal symptoms include abdominal pain, flatulence, bloating, and changes in bowel habits related to stool frequency and consistency, in the absence of detectable structural and biochemical abnormalities1,2. The prevalence is estimated at 5-10% among different ethnicities3. A low FODMAP diet is the most common dietary intervention with clinically proven benefits in symptom management and quality of life improvement of patients with Irritable Bowel Syndrome (IBS)4.
Interventions
- digestive enzymes Dietary supplement
Locations
1 country: Greece.
| Facility | City | Country |
|---|---|---|
| Attikon University General Hospital | Chaïdári, Athens | Greece |
| Attikon University General Hospital | Athens | Greece |
TreatIBS is an informational site and does not provide medical advice. The research summarized here may not apply to your situation. Talk with a clinician before starting, stopping, or changing any treatment.
Listing only. Eligibility is decided by the study team. TreatIBS is not involved in recruitment.